PARIS
Research type
Research Study
Full title
A Phase I Study of Pembrolizumab anti PD-1 monoclonal antibody in combination with Radiotherapy in locally advanced Non-Small Cell Lung Cancer (NSCLC) - PARIS
IRAS ID
217730
Contact name
Corinne Faivre-Finn
Contact email
Sponsor organisation
The Christie NHS Foundation Trust
Eudract number
2017-000444-17
Duration of Study in the UK
3 years, 9 months, 31 days
Research summary
Lung cancer is the leading cause of cancer mortality worldwide and in the U.K alone; there are 38,000 new cases of non-small cell lung cancer (NSCLC) a year. The new treatment being tested in this study is called pembrolizumab, this is a type of immunotherapy, which works by stimulating the body’s own immune system to fight cancer cells. Pembrolizumab blocks a protein on the T-cell surface (one of the cells of the immune system), which then triggers the cell to find and kill cancer cells. This will be given with radiotherapy to see if this combination is safe and effective at treating patients with non-small cell lung cancer.\nPembrolizumab has proved to be a safe and effective treatment for other cancers such as melanoma and lung cancer. Radiotherapy is often given as standard treatment in the NHS to treat lung cancer, and is proven to be a safe and tolerable treatment.
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
17/NW/0242
Date of REC Opinion
22 May 2017
REC opinion
Favourable Opinion